PDA

View Full Version : MD Anderson and Summit Therapeutics partner to accelerate ivonescimab development


News
07-25-2024, 10:01 AM
The University of Texas MD Anderson Cancer Center and Summit Therapeutics, Inc. today announced a strategic five-year collaboration agreement for the purpose of accelerating the development of ivonescimab.

More... (https://www.news-medical.net/news/20240725/MD-Anderson-and-Summit-Therapeutics-partner-to-accelerate-ivonescimab-development.aspx)